Industry context
Atrium Therapeutics Inc [RNA]
Last Updated 24 Jun 2026 @ 10:33 (Exchange is open)
Last: $12.92
0.86%
-1.02 (↓)
GaG Algo Score™
v1.0
Short
-1.02 (↓)
Medium
-2.06 (↓)
Long
-1.81 (↓)
BUY
70.00%
return 9.28%
SELL
81.63%
return 96.45%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 5.98% | 5.98% | 0.00% |
| Loss % | -13.42% | -13.42% | 0.37% |
| Duration | 18.0d | 15d | 7.0d |
| Total Pivots Found | 4 |
| Gain/Loss Legs | 3 (1 Gain / 2 Loss) |
| Last Pivot | Bottom @ $11.55 on 2026-06-08 |
| Change since Last Pivot | $1.26 (10.91%) |
Next Pivot Prediction Last: $12.92
| Predicted Next Type | Top |
| Predicted Price (Avg) | $12.24 |
| Predicted Price (Median) | $12.24 |
| Predicted Price Range (~68%) | $12.24 - $12.24 |
| Change to Avg Target | $-0.68 (-5.26%) |
| Predicted Date (Avg) | 2026-06-26 |
| Predicted Date Range (~68%) | 2026-06-19 - 2026-07-03 |
| Basis | Based on 1 historical gains (Avg: 5.98%, Median: 5.98%, StdDev: 0.00%) and duration (Avg: 18.0 days, StdDev: 7.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Atrium Therapeutics Inc lost modestly, down -1.00%.
Atrium Therapeutics Inc (RNA) stock price lost some ground on Tuesday after the stock fell $-0.130 (-1.00%) from the previous session on normal volume. The stock slightly underperformed the market, lagging slightly behind the NASDAQ's 0.22% rise. With 242 376 shares traded, volume yesterday reached $3.10M. This was 21 359 shares more than the prior day. Compared to the 10-day average of 202 427 shares, volume was more than the average.
Atrium Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-16.7%), medium- (-16.7%), and long-term (-16.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Atrium Therapeutics Inc Support & Resistance Levels
The stock is trading above the closest support level at $12.80. approximately $0.01000 (0.08%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s112.8 -
Atrium Therapeutics Inc Evaluation
- Short score: -1.02
- Medium score: -2.06
- Long score: -1.81
Ownership flow
GetAGraph InsiderPower
Transactions
184
Buy power
2 554 387
Sell power
1 673 326
2026-01-21
Hughes Steven George
Sell
2026-01-21
Hughes Steven George
Sell
2026-01-21
Boyce Sarah
Sell
2026-01-21
Boyce Sarah
Sell
2026-01-21
Flanagan W. Michael
Sell
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
2.78%
Of outstanding shares
Short float
2.65%
Of tradable float
Days to cover
15.83
Short interest divided by average volume
Squeeze probability
4.50%
-2.11% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
6
EPS misses
4
Avg. surprise
1.26%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-05 | - | - | - | - |
| Q2/2025 | 2025-08-08 | - | $-0.930 | - | - |
| Q1/2025 | 2025-05-08 | $-0.900 | $-0.880 | -2.27% | 1.57M |
| Q4/2024 | 2025-02-27 | $-0.800 | $-0.760 | -5.26% | 2.97M |
| Q3/2024 | 2024-11-07 | $-0.650 | $-0.710 | 8.45% | 2.34M |
| Q2/2024 | 2024-08-09 | $-0.650 | $-0.760 | 14.47% | 2.05M |
| Q1/2024 | 2024-05-09 | $-0.790 | $-0.810 | 2.47% | 3.54M |
| Q4/2023 | 2024-02-28 | $-0.790 | $-0.540 | -46.30% | 2.19M |
Analyst view
Analyst targets
Consensus
$25.00
Median
$25.00
Low
$25.00
High
$25.00
News flow
Latest company news
Market coverage
prnewswire.com Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 23, 2026 prnewswire.com Atrium Therapeutics Reports First Quarter 2026 Financial Results May 14, 2026 prnewswire.com Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Apr 23, 2026 prnewswire.com Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 20, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
Atrium Therapeutics Inc is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid RNA therapeutics directly to the heart Their developmentstage portfolio currently includes ATR 1072 a siRNAbased therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome and ATR 1086 another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases Founded in 2025 Atrium Therapeutics is based in San Diego California
Navigation